Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CureTech, Ltd.
Otsuka steps into the ocular gene therapy field through a technology licensing deal worth up to $1.5bn with ShapeTX, which in turn further expands the US firm's global reach following a $3bn collaboration with Roche.
After a year of R&D collaboration, Otsuka has made a decision to acquire Canadian venture Mindset to further expand its neurological pipeline with new 5-HT2A agonists.
NodThera is a pioneer in the field of NLRP3 inflammasome inhibitors, and after overcoming drug development setbacks, believes it can compete in a field alongside rivals such as Roche, Novartis and Novo Nordisk.
The German biotech is spending some of its pandemic capital on two antibody-drug conjugate candidates from the Chinese firm, including one in Phase II development.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.